Search

A response by Harlan M. Krumholz and colleagues to a letter to the editor about their article "Reduction in Acute Myocardial Infarction Mortality in the United States: Risk-Standardized Mortality Rates From 1995-2006," published in a 2009 issue, is presented.

A letter to the editor is presented in response to the article "Use of Open Access Platforms for Clinical Trial Data" by A.M. Navar, M.J. Pencina, J.A. Rymer, D.M. Louzao, and E.D. Peterson which appears in a 2016 issue of the journal.

A reply is presented to a response to the authors' article "Association of Admission to Veterans Affairs Hospitals vs non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia."

A response by J. P. Curtis and colleagues to a letter to the editor about their article "Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator" in a 2009 issue is presented.

A response from the author of an article on the use of observation in calculating hospitalizations among Medicare beneficiaries is presented.

A letter to the editor is presented in response to the article "Reported Mortality Findings in Trials for Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation" by B. M. Psaty and R. A. Kronmal in a previous issue.

The authors' reply to a letter to the editor in response to the article "Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality," by E. H. Bradley and colleagues is presented.

The author's response to letters to the editor is presented for the article by J.S. Ross, et al, "Effect of blinded peer reviews on abstract acceptance."

Presents a reply to a letter to the editor of "The Journal of the American Medical Association" regarding acute coronary syndromes and regionalization of care. Discussion of an article by Rathore and colleagues found in a previous issue of the journal.

Presents a reply by JoAnne Foody and colleagues to letters to the editor about their article "Systolic hypertension in older persons."

A letter to the editor is presented in response to the article by Dr. Butler and colleagues on the 10 promoted strategies for reducing readmission for patients with heart failure in issue 310(19):2035-2036.

A response by Harlan M. Krumholz to a letter to the editor about his article on the improvement of the patient-centered decision-making process through a standardized and personalized informed consent document in the previous issue is presented.

A reply is presented by Drs. Thomas M. Morgan, Harlan M. Krumholz and John A. Pertus to letters to the editor about their article "Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study."

The letter agrees with readers' comments on the effectiveness of percutaneous coronary intervention in myocardial infarction patients.

Presents a reply by Vivek Murthy and colleagues to a letter to the editor about their article "Participation in cancer clinical trials: race-, sex-, and age-based disparities."

Presents a reply from the authors of an article about racial disparities in the care of heart failure which appeared in a previous issue of the 'Journal of the American Medical Association.'

Presents a reply by the authors of an article previously published in the 'Journal of the American Medical Association,' about the use of digoxin in the treatment of heart failure.

The article discusses a proposal to conduct an external review of data related to research on the safety and efficacy of bone morphogenetic protein-2 (BMP-2). A spinal fusion product called Infuse Bone Graft from Medtronic Inc. contains recombinant BMP-2, which was approved by the U.S. Food and Drug Administration (FDA) for single level anterior interbody lumbar fusion in 2002. Skepticism towards the product is said to have increased as its use increased. There were conflict-of-interest issues raised in different periodicals such as the "Milwaukee Journal Sentinel" and "The Spine Journal." Professor Harlan M. Krumholz of Yale University School of Medicine in New Haven, Connecticut conceptualized the external review, which is being supported by Medtronic.

The article discusses the similarity in terms of efficacy and safety between coronary artery bypass graft (CABG) surgery combined with optimal medical therapy and medical therapy alone when used as treatment for coronary artery disease and left ventricular dysfunction. The Surgical Treatment for Ischemic Heart Failure (STICH) trial found that the two strategies have little difference in reducing mortality. Professor Harlan M. Krumholz of Yale University School of Medicine in New Haven, Connecticut questioned why cardiologists still offer CABG to patients in a shared decision-making environment. STICH coinvestigator Robert O. Bonow concluded that medical therapy should be offered to older patients with comorbid conditions while CABG to younger patients without comorbid conditions.